Peg-asparaginase for acute lymphoblastic leukemia

Bibliography

• Huguet F, Leguay T, Raffoux E, Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009;27(6):911-18 erratum in 27(15):2574
   PubMed Web of Science ®Google Scholar
• Ribera J, Oriol A, Sanz MA, Comparison of the results of the treatment of adolescents and young adults with standard risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 2008;26(11):1843-9
   PubMed Web of Science ®Google Scholar
• Silverman L, Declerck L, Gelber RD, Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1985) Leukemia 2000;14(12):2247-56
   PubMed Web of Science ®Google Scholar
• Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? Expert Opin Biol Ther 2009;9(1):111-19
   PubMed Web of Science ®Google Scholar
• Fu C, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother 2007;8(12):1977-84
   PubMed Web of Science ®Google Scholar
• Avramis V, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokin 2005;44(4):367-93
   PubMed Web of Science ®Google Scholar
• Asselin B, Whitin JC, Coppola D, Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-6
   PubMed Web of Science ®Google Scholar
• Panosyan EH, Seibel NL, Martin-Aragon S, Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961 J Pediatr Hematol Oncol 2004;26(6):333-5
   PubMed Web of Science ®Google Scholar
• Armstrong JK, Hempel G, Koling S, Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110(1):103-11
   PubMed Web of Science ®Google Scholar
• Pinheiro JP, Wenner K, Escherich G, Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2500 IU/m2 PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer 2006;46:18-25
   PubMed Web of Science ®Google Scholar
• Pinheiro JP, Muller HJ, SchwabE D, Drug monitoring of low-dose PEG-asparaginase (Oncospar TM) in children with relapsed acute lymphoblastic leukaemia. Br J Hematol 2001;113:115-19
   PubMed Web of Science ®Google Scholar
• Rizzari C, Citterio M, Zucchetti M, A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 2006;91(1):24-31
   PubMed Web of Science ®Google Scholar
• Hawkins D, Park JR, Thomson BG, Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10:5335-41
   PubMed Web of Science ®Google Scholar
• Dinndorf P, Gootenberg J, Cohen MH, FDA drug approval summary: pegaspargase (oncospar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007;12(8):991-8
   PubMed Web of Science ®Google Scholar
• Wenner Ka, Vieira Pinheiro JP, Escherich G, Asparagine concentration in plasma after 2,500 IU/m2 PEG-asparaginase i.v. children with acute lymphoblastic leukemia. Klin Padiatr 2005;217(6):321-6
   PubMed Web of Science ®Google Scholar
• Taylor CW, Dorr RT, Fanta P, A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginae in patients with advanced solid tumors. Cancer Chemother Pharmacol 2001;(47):83-88
   PubMed Web of Science ®Google Scholar
• Appel IM, Kazemier KM, Boos J, Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia; results from a single agent window study. Leukemia 2008;22:1665-79
   PubMed Web of Science ®Google Scholar
• Aguayo A, Cortes J, Thomas D, Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 1999;86(7):1203-9
   PubMed Web of Science ®Google Scholar
• Ettinger LJ, Kurtzberg J, Voûte PA, An open-label, multicenter study of polyethylene glycol-L-asparaginase of the treatment of acute lymphoblastic leukemia. Cancer 1995;75:1176-81
   PubMed Web of Science ®Google Scholar
• Kurtzberg J Moore JO, Sandierg D, A phase II study of polyethylene glycol (PEG) conjugated L-asparaginase in patients with refractory acute leukemia. Proc of AACR 1988;29:848
   Google Scholar
• Abshire TC, Pollock BH, Billett AL, Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood 2000;96(5):1709-15
   PubMed Web of Science ®Google Scholar
• Douer D, Yampolsky H, Cohen LJ, Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007;109(7):2744-50
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Baumann A, Beck J, PEG-asparaginase in adult acute lymphoblastic leukemia (ALL): efficacy and feasibility analysis with increasing dose levels. ASH Annual Meeting Abstracts. Blood 2008;112:302
   Web of Science ®Google Scholar
• Rytting M, Earl M, Douer D, Toxicities in adults with acute lymphoblastic leukemia (ALL) treated with regimens using pegasparaginase. Blood (ASH annual meeting abstracts) 2008;112:1924
   Web of Science ®Google Scholar
• Wetzler M, Sanford B, Kurtzberg J, Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and leukemia group B study 9511. Blood 2009;109(10):4164-7
   Web of Science ®Google Scholar
• Silverman L, Gelber RD, Dalton VK, Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01. Blood 2001;97:1211-18
   PubMed Web of Science ®Google Scholar
• Avramis V, Sencer S, Periclou AP, A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002;99:1986-94
   PubMed Web of Science ®Google Scholar
• Asselin BL, Kreissman S, Coppola DJ, Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999;21(1):6-12
   PubMed Web of Science ®Google Scholar
• Graham M. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003;55:1293-302
   PubMed Web of Science ®Google Scholar
• Rosen O, Muller HJ, Gokbuget N, Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br J Haematol 2003;123(5):836-41
   PubMed Web of Science ®Google Scholar
• Storring J, Minden M, Kao S, Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Hematol 2009;146:76-85
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Kenet G, Mitchell L. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiolgy, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 2009;22(1):103-14
   PubMed Web of Science ®Google Scholar
• Grace RF, Dahlberg S, Neuberg D, The frequency and management of asparaginase-related thrombosis in pediatric and acute patients with acute lymphoblastic leukemia treated on the Dana-Farber Cancer Institute (DFCI) Consortium Protocols. [Abstract 3073], 51st ASH Annual Meeting and Exposition; 2009
   Google Scholar